0.745
Schlusskurs vom Vortag:
$0.7495
Offen:
$0.7569
24-Stunden-Volumen:
718.51K
Relative Volume:
0.36
Marktkapitalisierung:
$138.50M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-0.5103
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
+6.65%
1M Leistung:
-0.82%
6M Leistung:
-26.88%
1J Leistung:
-46.73%
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
0.7442 | 125.53M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.24 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
446.93 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.95 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
485.38 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
2024-09-30 | Fortgesetzt | BTIG Research | Buy |
2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
2022-05-31 | Fortgesetzt | Jefferies | Hold |
2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-03-14 | Herabstufung | Stifel | Buy → Hold |
2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
2021-09-10 | Eingeleitet | BofA Securities | Neutral |
2021-06-28 | Hochstufung | Stifel | Hold → Buy |
2021-05-18 | Fortgesetzt | Goldman | Neutral |
2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
2021-01-06 | Eingeleitet | Stifel | Hold |
2020-09-14 | Eingeleitet | JP Morgan | Neutral |
2020-06-10 | Herabstufung | CFRA | Hold → Sell |
2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
2019-10-24 | Eingeleitet | Oppenheimer | Perform |
2019-10-08 | Herabstufung | Goldman | Buy → Sell |
2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
2018-12-13 | Eingeleitet | Goldman | Buy |
2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
2018-04-06 | Bestätigt | Mizuho | Buy |
2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com
BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World
What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st
Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World
GSK’s liver asset play grows group of $1B upfront deals - biocentury.com
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance
Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World
Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World
Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com
Nektar: Q1 Earnings Snapshot - The Washington Post
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses E - GuruFocus
Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timel - GuruFocus
Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c - StreetInsider
Nektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock News - GuruFocus
Nektar Therapeutics Q1 Loss Increases, Misses Estimates - Nasdaq
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nektar Therapeutics-Aktie (NKTR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Wilson Mark Andrew | Chief Legal Officer |
May 19 '25 |
Sale |
0.67 |
9,996 |
6,697 |
314,296 |
ROBIN HOWARD W | President & CEO |
May 19 '25 |
Sale |
0.67 |
23,208 |
15,549 |
1,063,693 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):